Dr. Kazandjian at the Sylvester Comprehensive Cancer Center discusses his role in the development of novel immunotherapies, specifically bispecific therapies, for Myeloma precursor diseases. He also explains the importance of BCL2 inhibitors in the treatment of Myeloma and how they work to prevent apoptosis. Dr. Kazandjian expresses his excitement for the future of Myeloma drug development and the increasing need for precision medicine.

The HealthTree Foundation for Multiple Myeloma brings information from the experts to the patients! Learn more at https://www.healthtree.org/myeloma/co...

Donate to the HealthTree Foundation for Multiple Myeloma or learn more about additional myeloma support we offer here: https://give.healthtree.org/campaign/...

HealthTree Cure Hub helps you find your best treatment options and accelerate a cure for multiple myeloma. Join today at https://www.healthtree.org/

Follow HealthTree:
twitter.com/healthtreeformm
facebook.com/healthtreeformultiplemyeloma
instragram.com/healthtreeformultiplemyeloma